Regression of BRAF(V600E) mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases

BACKGROUND: Up to 15% of young adults with glioblastoma have the activating oncogenic BRAF(V600E) mutation, an actionable target of the MAPK signal transduction pathway governing tumor cell proliferation. Small molecule inhibitors of BRAF and MEK, a downstream protein immediately following BRAF, hav...

Descripción completa

Detalles Bibliográficos
Autores principales: Woo, Peter Y.M., Lam, Tai-Chung, Pu, Jenny K.S., Li, Lai-Fung, Leung, Roland C.Y., Ho, Jason M.K., Zhung, James T.F., Wong, Belinda, Chan, Timonthy S.K., Loong, Herbert H.F., Ng, Ho-Keung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6557198/
https://www.ncbi.nlm.nih.gov/pubmed/31217909

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6557198/
https://www.ncbi.nlm.nih.gov/pubmed/31217909

Ejemplares similares